Unlock Practice Growth: Experience cvi42 at RSNA 2025See Why Leading Radiologists Are Upgrading to cvi42 This November - Visit Circle at RSNA Booth #7961
Circle CVI Announces FDA Clearance for cvi42 | Plaque for Coronary Artery Disease EvaluationCALGARY, Alberta, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Circle Cardiovascular Imaging Inc. (Circle CVI), a global leader in cardiovascular imaging solutions, today announced that its cvi42 | Plaque solution has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and is now available for clinical use in the United States. This innovative, AI-enabled solution allows clinicians to perform comprehensive coronary plaque analysis directly on-premise, enhancing diagnostic workflows and patient care.
